- Prescribing patterns for medical treatment of suspected prostatic obstruction: A
- 2 spatiotemporal statistical analysis of Scottish open access data
- 3 Authors
- 4 Federico Andreis, PhD [Faculty of Health Sciences and Sport, University of Stirling]
- 5 Richard Bryant, BMedSci MBChB FRCSEd(Urol) PHD [Nuffield Department of
- 6 Surgical Sciences, University of Oxford, Oxford Cancer Research Centre, Oxford] &
- 7 [Department of Urology, Churchill Hospital, Oxford University Hospitals NHS
- 8 Foundation Trust]
- 9 Emanuele Giorgi, PhD [Lancaster Medical School, University of Lancaster]
- Andrea Williamson, MBChB MPH PhD FRCGP FHEA DTM&H [General Practice and
- 11 Primary Care, School of Medicine, Dentistry and Nursing, MVLS, University of
- Glasgow] & [General Practitioner Homelessness Health, Medical Officer Addictions,
- 13 NHS Glasgow and Clyde, Homeless Health and Resource Services]
- 14 Ashleigh Ward, PhD [Faculty of Health Sciences and Sport, University of Stirling]
- 15 Corresponding author
- 16 Federico Andreis, PhD
- Faculty of Health Sciences and Sport, Pathfoot Building, University of Stirling, FK9
- 18 4LA, Stirling
- 19 email: federico.andreis@stir.ac.uk
- 20 tel: +44(0)1786466252
- 21 Word count 3790 (abstract: 277 / text: 3513, excl. figures, tables, equations and
- 22 captions)

23

27

29

36

45

24 **Background** Healthcare services treating men with prostate conditions are 25 increasingly burdened worldwide. One of the competing factors in this demand is 26 increasing diagnosis and treatment of lower urinary tract symptoms in men, much of which is suspected bladder outflow obstruction secondary to benign prostate hyperplasia/enlargement. However, the impact of increases on services is largely 28 hidden, and there is limited knowledge of potential differences in management based 30 on geography. Objective To investigate potential variation in the prescribing of drugs for suspected 31 32 bladder outflow obstruction in Scotland based on analysis of publicly available data, 33 and identify trends that may help to inform future prescribing behaviour. Design, setting, and participants We linked the relevant publicly available 34 35 prescribing and patient data to all general practices in Scotland between October 2015 and November 2019. 37 Outcome measurements and statistical analysis We analysed the numbers of daily doses of drugs prescribed for suspected bladder outflow obstruction per month 38 39 using a Bayesian Poisson regression analysis, incorporating random effects to 40 account for spatial and temporal elements in prescribing. 41 Results Prescriptions of drugs to treat suspected bladder outflow obstruction 42 increased during the observation period in Scotland, consistent with an ageing 43 population and increased diagnosis. Whilst some determinants of health inequality 44 regarding prescribing practices across health boards are consistent with those

known from the literature, other inequalities remain unexplained after accounting for

- 46 practice- and patient-specific characteristics such as socio-economic deprivation and
- 47 rurality.
- 48 **Conclusions** Variations in spatiotemporal prescribing for suspected bladder outflow
- obstruction exist in Scotland, some of which are unexplained and require further
- 50 investigation.

Keywords

51

- Suspected bladder outflow obstruction, benign prostate hyperplasia, benign prostate
- enlargement, lower urinary tract symptoms, drug prescription, open access data,
- 54 spatiotemporal modelling, medical practice

Introduction

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

The incidence of bothersome lower urinary tract symptoms (LUTS) in men, which are predominantly attributable to benign prostate hyperplasia (BPH) and/or benign prostatic enlargement (BPE) causing proven or suspected bladder outflow obstruction (BOO), is increasing globally [1] resulting in a reduced quality of life and increased healthcare expenditures [1, 2]. In Scotland as elsewhere in the United Kingdom and globally, some men may be managed conservatively or medically using drugs in the primary care setting for suspected or proven BOO (referred hereafter as BOO), whilst other men may have received investigation in a secondary care setting, before being recommended to receive medication in primary care. In Scotland healthcare services treating men with prostate conditions face an increasing burden from combinations of an ageing population, increased prostate cancer investigation and incidence [3], and increased awareness of male health issues. As a result of these combined factors, the impact of bothersome LUTS arising from BOO on service demand is largely hidden, and studies reporting their incidence and prevalence are predominantly cross-sectional in nature, with widely varying results [5]. Data regarding the prescription of drugs for the medical management of BOO as a cause for male bothersome LUTS has been used internationally in recent years to increase the understanding of patterns of prescribing within specific populations. This approach can be useful in order to identify potential demographic inequalities in patient's access to this aspect of healthcare, and to understand the patient experience, predominantly using longitudinal datasets [6, 7, 8]. However, to date there is limited understanding of how the prescribing patterns for drugs used to medically treat BOO may differ both spatially and temporally. The increasing

availability of high-quality open access healthcare data in Scotland has created the opportunity for a more refined and broader-based analysis of prescribing patterns for BOO. Moreover, Scotland's diverse geography provides an ideal landscape to understand how factors that may impact on prescribing patterns differ spatially in terms of geography, as well as longitudinally [9]. We describe a statistical framework that allows the study of variations in the patterns of drug prescribing in both space and time, while accounting for numerous relevant socioeconomic and health-related factors. We have used this approach in order to statistically analyse publicly available data regarding the prescription of the two main classes of medications used to treat bothersome LUTS secondary to BOO in Scotland. Using this approach, we describe spatiotemporal trends that may help inform future urological practice for this common and ubiquitous condition.

Material and Methods

Data sources

92

93

101

102

- 94 Data was acquired and linked from numerous independent and publicly accessible
- 95 sources. The dataset comprised information at the level of individual General
- 96 Practices (GPs) and was been created from the following four sources:
- NHS Scotland OpenData: drug prescriptions monthly data
 (https://www.opendata.nhs.scot/dataset/prescriptions-in-the-community)
- Information Services Division Scotland (ISD): practice details, deprivation,
 rurality (https://www.isdscotland.org/Health-Topics/General-Practice/)
 - National Institute for Health and Care Excellence (NICE): daily dosages (https://www.nice.org.uk)
- National Records of Scotland (NRS): postcodes, health boards
 (https://www.nrscotland.gov.uk/statistics-and-data/geography/our-products/scottish-postcode-directory/2018-2)

106 The keys used to link the sources were the unique GP code and date. The ISD and 107 NRS portals provided information regarding both the medical practice (i.e. GP) and 108 their patient population. Table 1 contains a list of the variables extracted from these 109 sources. We used both socio-economic deprivation and rurality to account for socio-110 demographic status. In particular, we used the 2016 Scottish Index of Multiple 111 Deprivation (SIMD) [10] and a recoded version of the 2018 Scottish Government 112 Urban Rural Classification [11]. Additionally, the ISD and NRS sources provided GP-113 level information regarding the size of the individual practice patient list, the gender 114 and age distribution, and the location of the practice (based on postcode and name 115 of relevant Health Board). It is important to note that digital boundaries of Scottish

GP practice catchment areas are not available; as a consequence, the spatial reference for both the GP practice- and patient-level data is the GP practice address. All GP practices open for the whole study period (October 2015 to November 2019) were included in the dataset (903 of 944, 95.7%, practices in Scotland open as of 1st January 2019). The Scottish Open Data portal provided the prescribed amounts of the drugs of interest per month.

Table 1. Variables extracted from the four data sources and used as covariates in the statistical model.

Variable	Туре	Short description
Drug group	Categorical	α-1 blocker or 5-α reductase inhibitor
GP patient list size	Numerical, time-varying	Number of registered patients per GP practice
GP practice run	Categorical, baseline	Is the practice run by GPs (contract type 17J and 17C), rather than by the NHS (contract type 2C)? Yes/No
Dispensing GP practice	Categorical, baseline	Does the GP practice have a license to dispense medicines? Yes/No
Males 45p	Numerical, time-varying	Proportion of patients that are males aged ≥45 years
Deprived 15	Numerical, time-varying	Proportion of patients under the 15 ["] national percentile of deprivation (SIMD)
Remote	Categorical, time-varying	Modal rurality index among the patients (Scottish Government 8-fold Urban Rural Classification) recoded as remote (4, 5, 7, 8) or non-remote (1, 2, 3, 6). Yes/No
Postcode	Categorical, baseline	GP practice postcode as of 2019
Health board	Categorical, baseline	Name of Scottish Health Board where the GP practice is situated.

BOO medications analysed

We specifically focussed on the prescribing of α -1 blocking drugs and 5- α reductase inhibitors as these are the only specific medications used for BOO. α -1 blockers are the first-line and most commonly used drugs prescribed for LUTS secondary to BOO [1, 12], whilst 5- α reductase inhibitors are generally recommended where men are considered at high risk of BPH progression due to a significantly enlarged prostate, either as monotherapy or in combination with α -1 blockers [1, 12, 13]. The α -1 blockers alfuzosin and tamsulosin hydrochloride were included in the study, however doxazosin and terazosin were not included as the amounts of these drugs prescribed

were negligible, whilst doxazosin may be prescribed for hypertension. The $5-\alpha$ reductase inhibitors dutasteride and finasteride were both included in this study. When combined with the suggested daily dosages from the NICE website (see Table 2), a proxy for the number of daily doses was constructed by rounding to the nearest integer the following expression:

$$n_{dti} = \frac{\text{\#tablets of drug } d \text{ prescribed during month } t \text{ at practice } i}{\text{daily suggested dosage for drug } j} \#(1)$$

where i, d, and t represent the GP practice, drug, and month respectively. In our dataset, we have observations for i=1,...,903 GP practices over t=1,...,50 months; d indexes the drugs reported in Table 2. The number of daily doses for each of the drug groups was then constructed by summation of the respective drugs' monthly amounts of daily doses. We denote with n_{jti} the number of daily doses of drugs belonging to group $j \in \{\alpha 1 - \text{blocker}, 5 - \alpha \text{ reductase inhibitor }\}$, prescribed during month t, at each GP practice i.

Table 2. Suggested daily dosages of the study α -1 blockers and 5- α reductase inhibitors according to NICE guidelines.

Drug	Drug group	Suggested daily dosage (NICE)
Alfuzosin	α-1 blocker	2.5 mg 3 times a day
Tamsulosin cap/tab Dutasteride	α-1 blocker 5-α reductase inhibitor	10 mg once daily 400mcg once daily 500mcg once daily
Finasteride	5-α reductase inhibitor	5mg once daily

We then used a Poisson model in order to describe the average number of daily doses of BOO medication prescribed each month, accounting for each of the covariates presented in Table 1, with additional spatial and temporal random effects. Possible interactions between the prescribing pattern of individual GP practices, or their geographical location, with the prescribed drug type were also investigated.

Equation 1 describes the model's functional form, while Table 3 summarises our choices in terms of spatial and temporal structure. Further details of the statistical analysis are provided as supplementary material.

$$n_{jti} \sim \text{Poisson}(\lambda_{jti})$$

$$\log(\lambda_{jti}) = \alpha + \alpha_{[i]} + \alpha_{[ji]} + \alpha_{[tji]} + \beta_1 \log(\text{list size}_{ti}) + \beta_2 \text{drug group} + \beta_3 \text{contract}_i + \beta_4 \text{dispensing}_i + \beta_5 \text{males } 45 \text{p}_{ti} + \beta_6 \text{deprived } 15_{ti} + \beta_7 \text{remote}_{ti} \# (2)$$

where j (drug group), t (month), and i (each GP practice) are as described, and $\alpha_{[i]}, \alpha_{[ji]}, \alpha_{[tji]}$ denote the random effects, summarised in Table 3. A detailed discussion of the choice of the random components of the model is available in the technical supplement.

Table 3. Spatial and temporal random effects.

Parameter	Туре	Short description
$\alpha_{[i]}$	Spatial	intrinsic Conditional Auto Regressive (iCAR)
$lpha_{[ji]}$	Unstructured	Unstructured interaction between GP and drug type
$\alpha_{[tji]}$	Temporal	First-order Auto Regressive (AR1), grouped by health board and drug type

Computational analysis

All computational analyses were carried out in R 3.6.1 [14]. We estimated the model parameters within the Integrated Nested Laplace Approximation framework using the inla package [15].

Results:

We investigated the effects of each the available covariates (including GP patient list size; BOO drug group; whether the practice was GP run; whether the GP practice dispensed medication; proportion of males aged 45 years; higher proportion of socioeconomic deprivation; and remote/rural location) on the study outcome. Table 4 summarises the output of the Poisson regression estimates of each of the associated parameters. In a further analysis, we interpreted each of these parameters in terms of relative differences from the model average (with the exception of GP practice list size).

Table 4. Summary of estimated posterior distributions for fixed effects. This summarises the model estimates of the fixed effect, and the uncertainty surrounding the estimates.

	Mean	SD	2.5%	50%	97.5%	Mode
α – Intercept	-1.570	0.040	-1.648	-1.570	-1.492	-1.570
β_1 – log(GP patient list size)	0.915	0.002	0.911	0.915	0.919	0.915
$β_2$ – Drug group (5-α reductase inhibitors)	-0.625	0.017	-0.658	-0.625	-0.591	-0.625
β_3 – GP run practices	0.238	0.033	0.174	0.238	0.302	0.238
β_4 – Dispensing GP practice	-0.086	0.026	-0.138	-0.086	-0.035	-0.086
β ₅ – Males aged ≥45 years	4.816	0.032	4.754	4.816	4.879	4.816
$oldsymbol{eta_6}$ – Socially deprived area	0.017	0.007	0.003	0.017	0.030	0.017
β_7 – Remote/rural GP practice	0.002	>0.001	0.002	0.002	0.003	0.002

The GP practice patient list size was observed to have an effect consistent with an estimated increase of slightly less than one daily dose per month per additional patient (point estimate 0.915). As expected, the prescribed doses of the $5-\alpha$ reductase inhibitor drug group were observed to be on average less than the

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202


203

204

205

206

prescribed doses of the $\alpha-1$ blocker drug group. The estimated relative difference was calculated to be on average 45-48% fewer 5 – α reductase inhibitor drug prescriptions than $\alpha - 1$ blocker drug prescriptions per month (point estimate 46%). We observed that the nature of how the GP practices are individually run are associated with BOO drug-prescribing practice, with GP-run practices (rather than by direct Health Board-run practices) having larger volumes of these prescriptions. The model results are consistent with a 19-35% (point estimate 27%) increased number of monthly prescriptions for GP-run practices compared with Health Board-run practices, all else being equal. This is an interesting result, and to the best of our knowledge no rigorous research has been undertaken to investigate the role that how a GP practice is managed plays on the stability of GP provision of care and, in turn, on patient help seeking behaviours and clinical outcomes. Conversely, we observed that the small number of GP practices who run their own dispensary are associated with 3-13% (point estimate 8%) lower volumes of BOO drug prescriptions, compared to GP practices who do not, keeping all other variables constant. Practices that dispense tend to do so because there is no local community pharmacy, and one is needed for patient care. It is plausible that having a dispensing licence may reflect an aspect of remoteness that is not captured by the rurality measure we employ. We found the proportion of males aged ≥45 years in the GP practice patient list to be positively associated with the volume of BOO prescriptions, with an estimated average increase of 4.9% monthly prescriptions per percentage point. In contrast, the levels of socio-economic deprivation, and a remote/rural geographical location of each GP practice, were found to have a negligible association with prescribing practice.



<u>Figure 1</u>: Statistical model average number of daily doses of each BOO drug type prescribed per month, by individual Scottish Health Board and adjusted for GP practice patient roll size.

Next, we investigated the statistical model's interpolations according to Health Board and drug group (α -1 blocking drugs and 5- α reductase inhibitors) (**Figure 1**). This analysis highlighted a general increase in the volumes of prescriptions for these medications over the 4-year study period. Trends in prescribing were observed to be broadly similar across most Health Boards, with a less prominent increase in less populated areas, which may potentially be attributable to a more stable population structure over the 4-year period of observation, as well as unaccounted for differences in help seeking behaviours. Within most Health Boards the growth in prescriptions for each drug group were almost parallel during the four-year

observation period, suggesting consistency in terms of increased BOO drug prescribing. Additional observations included a marked shift in volumes of α -1 blocking drug prescriptions in Lanarkshire between November 2016 and February 2017, however no further specific information regarding this phenomenon was available within the publicly available dataset. In the absence of a reasonable explanation for this singular observation in this one Health Board, this has been treated as an artefact due to a change in data-recording.




Figure 2: Frequency histograms of the statistical model's exponentiated residuals for each Scottish Health Board. The vertical dashed line represents the null residual (value=1 on the exponentiated scale), and each small black square represents the average number of daily prescriptions of BOO drugs (combined $\alpha-1$ blockers and $5-\alpha$ reductase inhibitors) per month per individual anonymous GP practice within each Health Board. The boxplot below each histogram illustrates the same data

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

distribution (the white point marks the median, the thick line represents the usual box, and the thin line represents the whiskers). Ideally the exponentiated residuals for each GP practice would lie around the null residual (i.e. value=1), however the heterogeneity in prescribing practice is illustrated by increased spread to the left and right of the null residual. A shift of GP practice distributions to the right of the null residual, as seen in Health Boards such as Borders, Fife, Orkney, Shetland and Tayside, illustrates less prescribing of these medications than would be expected. Next, we investigated how the statistical model residuals may provide insight into how BOO drug prescribing behaviour differed across Scotland during the 4-year study period. Figure 2 illustrates histograms of exponentiated residuals for each individual Health Board across Scotland, where a reference value of $1 = e^0$ represents a null residual (i.e. there is no deviation from the model's predicted average). Each residual is specific to one individual anonymous GP practice. On an exponential scale, a value of 1 indicates a prescribing behaviour in line with the average as described by the statistical model across Scotland during the study period. A value below 1 indicates prescribing volumes higher than expected based on the model, whilst a value larger than 1 indicates prescribing volumes lower than expected. Asymmetry around the reference value of 1, and/or multiple modes of distribution, suggests a different behaviour of individual GP practices within a Health Board compared against the national average across Scotland. Using this statistical approach, we generally observed consistency in the prescription of drugs for BOO across Health Boards in Scotland, with most distributions appearing to be approximately unimodal and symmetric around the null residual (i.e. the reference value of $1 = e^0$). However, some interesting patterns of prescribing can be observed, such as the reduced level of BOO drug prescribing in some individual Health Boards (most notably Borders, Forth Valley, Tayside, Orkney and Shetland) compared to the average prescribing rate across Scotland. The reasons for these

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

differences in prescribing pattern in these individual Health Boards are unclear and require further investigation. Next, we examined the BOO drug prescribing patterns of GP practices with the aim of assessing and visualising possible spatial patterns. Once again using the model residuals, it was possible to identify individual anonymous practices at the extremes of the BOO prescribing distribution, and show their Health Board location on a map. This approach can be useful in order to detect geographic clusters of similar prescribing patterns, while accounting for temporal trends and other potential confounding factors that are already included in the model. For example, the policymaker might be interested in identifying clusters of GP practices where the rates of prescribing are either very low or very high with respect to the national average. We present the results of such analysis in Figure 3 where, to preserve anonymity of the individual practices, we have aggregated the information at the Health Board level. We denote those GP practices with a model residual below the 2.5% percentile of the overall distribution of residuals as "high-volumes prescribers", and those above the 97.5% percentile as "low-volumes prescribers". We stress that high- and low- are with respect to the national average as described by the model Moreover, the quantile thresholds are arbitrary and can be adjusted according to the analytical need.




Figure 3: Maps of Scotland highlighting the Health Board locations of anonymous GP practices at the extremes of the distribution of BOO drug prescribing. The left panel shows the percentage of GP practices within each Health Board that have been identified (via model residuals) as being high in prescribing volumes with respect to the national average (i.e. model residuals <2.5% percentile). Similarly, the right panel shows the percentage of GP practices low in prescribing volumes with respect to the national average (i.e. model residuals >97.5% percentile). We observed that Highland is the Health Board with the largest percentage (~9.5%) of GP practices that were identified as being in the upper tail of prescribing volumes (identified by model residuals <2.5% percentile), followed by Lothian (~5.3%), Dumfries and Galloway (~3.2%), Grampian (~2.9%), Forth Valley (~2%) and Greater Glasgow and Clyde (~1.7%). No high-volume prescribing GP practices were found within the remaining Health Boards. On the other hand, Tayside was identified as the Health Board with the largest percentage (~19%) of low-volume prescribers (identified by model residuals >97.5% percentile). Shetland (10%), Borders (~8.7%), Grampian (~5.7%), Highland (~1.1%), Lothian (~1%), and Greater Glasgow and Clyde (~0.9%) also contained GP practices that prescribed far below the national

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

average. The remaining Health Boards did not contain any low-volume prescribing practices. The underlying reasons for these observations are currently unclear and require further investigation.

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

This study has investigated patterns of medical prescribing for the two most common classes of drug (i.e. $\alpha - 1$ blockers and $5 - \alpha$ reductase inhibitors) used to treat BOO in Scotland over a recent 4-year period (October 2015 - November 2019) using publicly available data from individual GP practices across all Health Boards. Using this approach we generated a study dataset by linking prescribing data to GP practice-specific information (such as their type of contract with NHS, and their licence to dispense) and summary characteristics of their patient populations (such as patient age, and GP practice-associated levels of socio-economic deprivation and rurality). This has enabled us to develop an improved understanding of patterns of prescribing of these medications across Scotland, and identify where prescription volumes may vary, having accounted for these variables. A trend of increased BOO drug prescribing practice was observed throughout the 4year observation window consistent with an ageing Scottish population, and perhaps also due to an increased awareness of male health issues amongst both patients and general practice teams, and increased referral of men to secondary care due to a raised PSA, which may indicate BPH as well as possible prostate cancer [16, 17]. However, it would be interesting to understand more fully the reasons behind the observed increase in prescribing across all Scottish Health Boards, and the role that increased awareness and patient help seeking behaviour may play in this phenomenon. It may also be interesting to identify the relative contribution (or otherwise) made by increased referral to secondary care with suspected prostate cancer (as identified by a raised PSA), which might result in increased BOO/BPH prescribing as a secondary consequence of a raised PSA referral. A further possibility may be that an increased focus on cancer management, rather than BPH

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

surgery, may lead to an increase in medical drug use for BOO, rather than definitive intervention – this is speculative, but would be very interesting to investigate in future studies, particularly in order to investigate how this may vary geographically. Although it has been acknowledged that aspects regarding individual GP medical practices may potentially contribute to prostate health inequalities [18, 19], to our knowledge this is the first time that the particular characteristics of a GP practice (such as patient ages, GP-run practices, dispensing ability, socio-economic deprivation levels, and rurality) have been identified as being potential factors influencing BOO drug prescribing patterns. It was interesting to observe that whether a practice was Health Board or GP-run, and whether a dispensing pharmacy was present within the GP practice, was associated with higher and lower prescribing volumes respectively. While the individual characteristics of GP medical practices are known to differ by region [20], research accounting for these factors is relatively sparse; hence it is unclear why this difference exists. This study has several limitations. Firstly, the available data only exists in the public domain at an aggregate (i.e. individual GP practice or patient list) level, and further information would be helpful in order to identify the reasons why prescribing practices vary at a more granular level (perhaps by associating the prescribing practice with the presence or absence of a GP with a particular interest in men's health issues, as an example). Secondly, the use of summary data regarding levels of socio-economic deprivation and rurality of patients reduces the accuracy with which one can estimate the shape of their association with outcome, with these factors likely to be important in terms of access to healthcare and prescribing. Similarly, not having information about specific GP practice catchment areas made it necessary to use an adjacency matrix based on postcodes, rather than actual

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

distances, resulting in a sub-optimal method of accounting for underlying spatial processes; furthermore, future work utilising anonymised individual-level patient data would also help to increase accuracy. Finally, it would be useful to analyse potential relationships between BOO drug prescribing patterns and longer-term outcomes from BOO in terms of clinical progression of this condition, such as need for future surgical intervention or treatment for BOO complications, such as acute urinary retention, and how they relate to investigation for suspected cancer or raised PSA. Such an analysis requires additional hospital data which in future work could be accessed via established high-quality data linkage systems in the Scottish National Safehaven. It would also be interesting to understand the relative contribution of patient ageing to the rate of rise in BOO drugs prescription, and the degree to which other factors such as help-seeking behaviour and clinician awareness might be contributing to this rate of rise in prescription volumes. These possibilities require further investigation. Nevertheless, despite these caveats and limitations, the analyses presented herein have identified interesting BOO medical prescribing trends across Scotland that require further investigation in future studies. In addition to identifying influences from spatial, temporal, and socioeconomic factors in regards to volumes of prescription of BOO medications, our analysis suggests that other sources of variability might account for inequalities in prescribing practice. In recent decades a considerable amount of research has been undertaken in order to better understand complex health-related phenomena whose determinants might transcend socio-demographic factors, and can best be described by a unique regional culture or a strong 'social patterning' [21, 22]. Although at this stage it is

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

conditions in a range of future studies.

unclear what the remaining hidden determinants of the variations in BOO drugprescribing patterns may be, Scotland's cultural diversity as described in the wider literature may constitute a potential explanation [9]. This warrants further investigation in future research. It would be interesting for future research to investigate trends and potential inequalities regarding all prostate-related conditions (both benign and malignant) over space and time in other settings and geographical locations. In particular, it would be interesting to investigate whether the trends observed in Scotland may similarly exist in other regions of the UK and Ireland, and if so, are variations attributable to common factors such as remoteness/rurality and socio-economic status. Further research to investigate medical practice phenomena as complex as prescribing patterns using publicly available data may identify key limitations in practice, and may inform data collection and data sharing in the future. In addition, the general nature of the statistical modelling framework we have proposed in this study may be extended to investigate other kinds of models, covariates, and medical

Conclusions

The volume of prescriptions of drugs for LUTS secondary to BOO has steadily increased across Scotland during a recent 4-year observation period, which may, at least in part, be attributable to an ageing population and increased diagnoses.

Prescription volume for these medications is associated with various characteristics of the GP practice (such as type of contract and presence of a licence to dispense). However, some inequalities in prescribing across Health Boards in Scotland remain unexplained after accounting for GP practice- and patient-specific characteristics such as socio-economic deprivation and rurality, suggesting there may be other hitherto unknown determinants of BOO drug prescribing practice. Further research is warranted to understand these differences more fully.

Acknowledgements

- The authors would like to acknowledge support and encouragement received by Prof
- 400 Alan McNeill (NHS Scotland) and Prostate Scotland at the initial conception of this
- 401 project.

398

399

402

403

References

- [1] European Association of Urology. EAU guidelines on non-neurogenic male LUTS.
- 405 2019.
- 406 [2] Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia
- and bladder outlet obstruction. Indian J Urol 2014;30:170—6.
- 408 [3] Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer
- survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025
- patients diagnosed with one of 18 cancers from 322 population-based registries in
- 411 71 countries. Lancet. 2018; 391:1023–75.
- [4] NHS National Services Scotland. Cancer waiting times. NHS National Services
- 413 Scotland. 2019.
- 414 [5] Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms
- suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis.
- 416 Sci Rep. 2017;7(1):7984. doi: 10.1038/s41598-017-06628-8.
- 417 [6] Bajic P, Montgomery J, Nelson M et al. (2020). 133 comparisons fo BPH
- 418 medication prescribing among sexagenarians with Medicare an private insurance. J
- 419 Sex Med. 2020; 17(1):37—38.

- [7] Fu Y, Han S, Wang L, Geo W, Cao X, Wang J. Comparison of characteristics of
- benign prostatic hyperplasia (BPH) patients treated with finasteride and alpha
- 422 blocker combination therapy verses alpha blocker monotherapy in China: An
- analysis of electronic medical record data. Adv. Ther. 2018; 35:1191—1198.
- [8] Moon HW, Yang JH, Choi JB, Bae WJ. Prescription pattern of alpha-blockers for
- management of lower urinary tract symptoms/benign prostatic hyperplasia. Sci Rep.
- 426 2018; 8.
- [9] Taulbut M, Walsh D, McCartney G et al. Spatial inequalities in life expectancy
- within post-industrial regions of Europe: A cross-sectional observational study. BMI
- 429 Open. 2014; 4.
- [10] Scottish Government. Scottish Index Of Multiple Deprivation. [online] available
- at: http://www.gov.scot/Topics/Statistics/SIMD [accessed 9 Mar 2020].
- [11] Scottish Government. Scottish Government Urban Rural Classification. [online]
- 433 available at:
- 434 https://www2.gov.scot/Topics/Statistics/About/Methodology/UrbanRuralClassification
- 435 [accessed 9 Mar 2020]
- [12] National Institute for Health and Care Excellence. LUTS in men. National
- Institute for Health and Care Excellence. 2019.
- 438 [13] McConnell JD, Roehrborn CG, Bautista OM et al. The Long-Term Effect of
- Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of
- Benign Prostatic Hyperplasia. Clinical Trial N Engl J Med. 2003 Dec 8;349(25):2387-
- 441 98. doi: 10.1056/NEJMoa030656.

- [14] R Core Team. R: A language and environment for statistical computing. R
- 443 Foundation for Statistical Computing, Vienna, Austria 2019. URL https://www.R-
- 444 project.org/.
- [15] H. Rue, S. Martino, and N. Chopin. Approximate Bayesian inference for latent
- Gaussian models using integrated nested Laplace approximations (with discussion).
- Journal of the Royal Statistical Society, Series B. 2009; 71(2):319--392.
- [16] National Records of Scotland. Mid-year population estimates Scotland, Mid-
- 449 2018. 2019.
- [17] European Association of Urology. EAU guidelines on prostate cancer. 2019.
- [18] Public Health England. Prostate cancer risk management programme: overview.
- 452 2016.
- [19] Clements A, Bukach C, Rai T, Shine B, Austoker J, Watson E. What influences
- men's decision to have a prostate-specific antigen test? A qualitative study. Family
- 455 Practice. 2007; 24.
- 456 [20] Burgess L. Primary Care in Scotland. The Scottish Parliament. 2018.
- 457 [21] Walsh D, McCartney G, Collins C, Taulbut M, Batty GD. History, politics and
- vulnerability: explaining excess mortality in Scotland and Glasgow. Public Health.
- 459 2017; 151:1—12.
- 460 [22] Cowley J, Kiely J, Collins D. Unravelling the Glasgow effect: The relationship
- between accumulative bio-psychosocial stress, stress reactivity and Scotland's
- health problems. Prev. Med. Rep. 2016; 4:370-375.